StockMarketWire.com - Specialist pharmaceuticals company N4 Pharma recorded an operating loss of £585,066 for the first half of 2020.

This was an improvement on the H1 2019 operating loss of £552,160, mainly driven by lower general and administration costs.

The company's Nuvec product, which is designed to deliver vaccines and cancer treatments, was successfully tested in connection with COVID-19 work as N4 Pharma redirected its efforts towards the pandemic.

During the period, the company raised £1.9m through a share issue, raising its cash level to £2.4m.


At 9:07am: (LON:N4P) N4 Pharma Plc Ord 0.4p share price was 0p at 6.25p



Story provided by StockMarketWire.com